HCM
BIO icon

Hoplite Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hoplite Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-47,599
Closed -$14.9M – 2
2019
Q2 		$14.9M Sell
47,599
-59,320
-55% -$17.8M 2.03% 20
2019
Q1 		$32.7M Buy
+106,919
New +$28.9M 3.91% 11

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Hoplite Capital Management's BIO Position: Q3 2019 in Review

Hoplite Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2019, closing a stake of 47,599 shares — an estimated $14.9M sold.

Hoplite Capital Management first reported a position in BIO in Q1 2019 and held it in 2 quarters. The position peaked at $32.7M in Q1 2019. 354 funds tracked by Wall St. Rank hold BIO as of Q3 2019.

  • Hoplite Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2019 after selling out during the quarter.
  • Hoplite Capital Management sold 47,599 Bio-Rad Laboratories Class A shares in Q3 2019, an estimated $14.9M.
  • Hoplite Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and held it in 2 quarters.
  • Hoplite Capital Management's Bio-Rad Laboratories Class A position peaked at $32.7M in Q1 2019.
  • 354 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2019.

Based on Hoplite Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.